Drug Trial Radar · NCT03861234
A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Jun 27, 2019
Primary completion
Nov 1, 2023
Study completion Nov 1, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study in people with an eye disease called wet age-related macular degeneration (wAMD). The purpose of the study is to find out how well different doses of a medicine called BI 836880 are tolerated. People can participate if they are at least 55 years old and if they have new blood vessels in their eyes despite treatment (anti-VEGF therapies). The study has 2 parts. In the first part, people get only 1 dose of BI 836880. This part takes 6 weeks. In the second part, people get 3 times the same dose of BI 836880. This part takes 6 months. BI 836880 is injected into the eye. During the entire study doctors regularly check the health of the participants.
Conditions
- Wet Macular Degeneration
Interventions
BI 836880Drug
Solution for Intravitreal (IVT) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- SRD-part: Number of Participants With Ocular Dose Limiting Events (DLEs)Time frame: From drug administration until the end of trial (EOT) visit in the SRD part, up to 6 weeks.
- MRD-part: Number of Participants With Drug Related Adverse Events (AEs)Time frame: From first drug administration until the end of trial (EOT) visit in the MRD part, up to 24 weeks.
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Associated Retina Consultants, Ltd.
Phoenix, Arizona
New York Eye and Ear Infirmary of Mount Sinai
New York, New York
Verum Research, LLC
Eugene, Oregon
Erie Retina Research, LLC
Erie, Pennsylvania
Retina Research Institute of Texas
Abilene, Texas
Austin Clinical Research, LLC
Austin, Texas
Retina Consultants of Texas
Bellaire, Texas
Charité - Universitätsmedizin Berlin
Berlin, Germany
Universitätsmedizin Göttingen, Georg-August-Universität
Göttingen, Germany
Universitätsklinikum Ulm
Ulm, Germany
Bristol Eye Hospital
Bristol, United Kingdom
Royal Liverpool University Hospital
Liverpool, United Kingdom
Moorfields Eye Hospital
London, United Kingdom
Sunderland Eye Infirmary
Sunderland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.